DOI: https://doi.org/10.24959/cphj.18.1471

Variability of the effect of atristamine and imipramine on the depressive behavior of mice in the aspect of circadian factors

I. M. Podolsky, S. Yu. Shtrygol’, V. V. Tsyvunin

Abstract


Chronophysiological features of secretion of some hormones and neurotransmitters (especially melatonin), which have distinct circadian and seasonal rhythms, are the main endogenous factors affecting the depressive behavior of both animals and humans. That is why it is possible to assume different sensitivity of the CNS in animals to the effect of antidepressant chemicals introduced in different phases of the day.

Aim. To study the variability of the effect of a promising antidepressant atristamine in comparison with the classical tricyclic antidepressant imipramine on the depressive behavior of mice taking into account chronophysiological (circadian) factors.

Materials and methods. The depressive behavior of mice was studied using the tail suspension test. Four experiments were performed within one day at the following time intervals: 2:00-4:00, 8:00-10:00, 14:00-16:00, 20:00-22:00. The cosinor analysis of the results was carried out using the Cosinor-Analisis 2.4 program.

Results. There were no significant differences during the day among the indicators of the intact control group. Animals treated with imipramine (25 mg/kg) had a lower total time of immobility (a marker of the antidepressant activity) in all time periods. In the daytime, the decrease of this indicator was maximal and statistically significant (–36.8 % against the intact control group, p<0.05). At night, on the contrary, this parameter was slightly different from that in the intact control group (–12.2 %). The total time of immobility of mice on the background of atristamine (100 mg/kg) did not differ from that of the intact control group in the morning. In the daytime, atristamine significantly reduced this indicator (–26.5 %, p<0.05) compared to the intact control. The effect of the test compound on the depressive behavior of mice was decreased in the evening. Animals of this group at night were on average 30 % longer in the state of “behavioral despair” compared to the control. The cosinor analysis showed that the animals of all experimental groups had a 24-hour sinusoidal chronorhythm of depressivity in the tail suspension test. The same type of displacement of acrophases of the depressive behavior parameters in mice relative to physiological values occurs after administration of atristamine and imipramine. Unlike tricyclic antidepressant imipramine, atristamine causes a pronounced daily oscillation of depressive behavior of mice.

Conclusions. Atristamine and imipramine significantly reduced the total time of immobility of animals only in the daytime period (14:00-16:00). The common chronopharmacological feature of the effect of atristamine and imipramine on the depressive behavior of mice is reduction of the antidepressant activities of both substances at night.


Keywords


2-methyl-3-(phenylaminomethyl)-1H-quinolin-4-one; atristamine; imipramine; the tail suspension test; circadian rhythms; cosinor analysis

References


Weil, Z. M., Hotchkiss, A. K., Gatien, M. L., Pieke-Dahl, S., & Nelson, R. J. (2006). Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Research Bulletin, 68(6), 425–429. https://doi.org/10.1016/j.brainresbull.2005.09.016

Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., … Cardinali, D. P. (2006). Melatonin in mood disorders. The World Journal of Biological Psychiatry, 7(3), 138–151. https://doi.org/10.1080/15622970600571822

A. Quera Salva, M., Hartley, S., Barbot, F., C. Alvarez, J., Lofaso, F., & Guilleminault, C. (2011). Circadian Rhythms, Melatonin and Depression. Current Pharmaceutical Design, 17(15), 1459–1470. https://doi.org/10.2174/138161211796197188

Guardiola-Lemaitre, B., De Bodinat, C., Delagrange, P., Millan, M. J., Munoz, C., & Mocaër, E. (2014). Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. British Journal of Pharmacology, 171(15), 3604–3619. https://doi.org/10.1111/bph.12720

Shtrygol', S. Iu., Zubkov, V. A., Podol'skiĭ, I. N., Gritsenko, I. S. (2012). Eksperimental'naia i klinicheskaia farmakologiia, 75 (4), 7–9.

Podolsky, I. M., Shtrygol’, S. Y., & Zubkov, V. O. (2018). The psycho- and neurotropic profiling of novel 3-(N-R,R′-aminomethyl)-2-methyl-1H-quinolin-4-ones in vivo. Saudi Pharmaceutical Journal, 26(1), 107–114. https://doi.org/10.1016/j.jsps.2017.10.005

Shtrygol′, S. Ju., Zubkov, V. O., Gritsenko, I. S., Podolsky, I. M., Shatilov, O. V. (2010). Klìnìčna farmacìâ, 14 (1), 35–38.

Podolsky, I. M., Shtrygol, S. Yu. (2016). Klìnìčna farmacìâ, 20 (4), 46–51. https://doi.org/10.24959/cphj.16.1408

Podolsky, I. M., Shtrygol, S. Yu. (2015). Neuroprotective activity of 2-methyl-3-phenylaminomethylquinolin-4-one in experimental traumatic brain injury in rats. Journal of Chemical and Pharmaceutical Research, 7 (4), 518–524.

Podolsky, I. M., Shtrygol′, S. Yu., Ostashko, V. F., Bezditko, N. V. (2013). Ukraïns'kij bìofarmacevtičnij žurnal, 2 (25), 46–49.

Shtrygol′, S. Yu., Podolsky, I. M., Zubkov, V. O., Gritsenko, I.S. (2013). Zastosuvannia 2-metyl-3-fenilaminometylkhinolin-4-onu yak zasobu antyhipoksychnoi, aktoprotektornoi ta antyalkoholnoi dii. Patent UA 102900 na vynakhid, MPK (2013.01) A61K 31/47 (2006.01), C07D 215/233 (2006.01), C07D 215/12 (2006.01), A61P 25/00, A61P 25/32 (2006.01). № a 2011 13575; declared 18.11.2011; published 27.08.2013, № 16, 4.

Podolsky, I., Shtrygol', S. (2017). The analgesic properties of a promising antidepressant – 2-methyl-3-(phenylaminomethyl)-1H-quinolin-4-one. The Pharma Innovation Journal, 6 (8C), 156–160.

Council Directive 2010/63/EU of 22 September 2010 on the protection of animals used for scientific purposes (2010). Official Journal of the European Communities, L 276, 33–79.

Zubkov, V. A., Gritsenko, I. S., Taran, S. G., Podolsky, I. N., Kamenetska, O. L. (2005). Žurnal organìčnoï ta farmacevtičnoï hìmìï, 3(2), 23–27.

Steru, L., Chermat, R., Thierry, B., Simon, P. (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl), 85, 367–370. https://doi.org/10.1007/bf00428203

Dauchy, R. T., Wren, M. A., Dauchy, E. M., Hoffman, A. E., Hanifin, J. P., Warfield, B., … Blask, D. E. (2015). The Influence of Red Light Exposure at Night on Circadian Metabolism and Physiology in Sprague-Dawley Rats. Journal of the American Association for Laboratory Animal Science: JAALAS, 54(1), 40–50.

Shtrygol′, S. Yu. (2007). Modulyatsiya farmakologicheskih effektov pri razlichnyih solevyih rezhimah: Monografiya. Kharkov: Avista-VLT, 360.

Cornelissen, G. (2014). Cosinor-based rhythmometry. Theoretical Biology and Medical Modelling, 11(1), 1–24. https://doi.org/10.1186/1742-4682-11-16

Marseglia, L., D’Angelo, G., Manti, S., Aversa, S., Arrigo, T., Reiter, R., & Gitto, E. (2015). Analgesic, Anxiolytic and Anaesthetic Effects of Melatonin: New Potential Uses in Pediatrics. International Journal of Molecular Sciences, 16(1), 1209–1220. https://doi.org/10.3390/ijms16011209


GOST Style Citations


1. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating / Z. M. Weil, A. K. Hotchkiss, M. L. Gatien [et al.] // Brain Res. Bull. – 2006. – Vol. 68, Issue 6. – P. 425–429. http://doi.org/10.1016/j.brainresbull.2005.09.016

2. Melatonin in mood disorders / V. Srinivasan, M. Smits, W. Spence [et al.] // World J. Biol. Psychiatry. – 2006. – Vol. 7, Issue 3. – P. 138–151. https://doi.org/10.1080/15622970600571822

3. Circadian rhythms, melatonin and depression / M. A. Quera Salva, S. Hartley, F. Barbot [et al.] // Curr. Pharm. Des. – 2011. – Vol. 17, Issue 15. – P. 1459–1470. https://doi.org/10.2174/138161211796197188

4. Pharmacological properties of the antidepressant agomelatine / B. Guardiola‐Lemaitre, C. De Bodinat, P. Delagrange [et al.] // Br. J. Pharmacol. – 2014. – Vol. 171, Issue 15. – P. 3604–3619. https://doi.org/10.1111/bph.12720

5. 2-Метил-3-фениламинометилхинолин-4-он – потенциальный антидепрессант с ноотропными свойствами / С. Ю. Штрыголь, В. А. Зубков, И. Н. Подольский, И. С. Гриценко // Экспер. и клин. фармакол. – 2012. – Т. 75, № 4. – С. 7–9.

6. Podolsky, I. M. The psycho- and neurotropic profiling of novel 3-(N-R,R′-aminomethyl)-2-methyl-1H-quinolin-4-ones in vivo / I. M. Podolsky, S. Yu. Shtrygol′, V. O. Zubkov // Saudi Pharm. J. – 2018. – Vol. 26, Issue 1. – P. 107–114. https://doi.org/10.1016/j.jsps.2017.10.005

7. Скринінгові дослідження 3-амінометил-2-метилхінолін-4-онів як потенційних психотропних засобів / С. Ю. Штриголь, В. О. Зубков, І. С. Гриценко [та ін.] // Клінічна фармація. – 2010. – Т. 14, № 1. – С. 35–38.

8. Подольський, І. М. Дозозалежність ефектів перспективного антидепресанта з ноотропними властивостями 2-метил-3-(феніламінометил)-1H-хінолін-4-ону / І. М. Подольський, С. Ю. Штриголь / Клінічна фармація. – 2016. – Т. 20, № 4 – С. 46–51. https://doi.org/10.24959/cphj.16.1408

9. Podolsky, I. M. Neuroprotective activity of 2-methyl-3-phenylamino-methylquinolin-4-one in experimental traumatic brain injury in rats / I. M. Podolsky, S. Yu. Shtrygol // J. Chem. Pharm. Res. – 2015. – Vol. 7, Issue 4. – P. 518–524.

10. Антигіпоксична активність 2-метил-3-феніламінометилхінолін-4-ону – перспективного антидепресанта з ноотропними властивостями / І. М. Подольський, С. Ю. Штриголь, В. Ф. Осташко, Н. В. Бездітко // Український біофармацевтичний журнал. – 2013. – № 2 (25). – С. 46–49.

11. Застосування 2-метил-3-феніламінометилхінолін-4-ону як засобу антигіпоксичної, актопротекторної та антиалкогольної дії. Пат. UA 102900 на винахід, МПК (2013.01) A61K 31/47 (2006.01), C07D 215/233 (2006.01), C07D 215/12 (2006.01), А61Р 25/00, А61Р 25/32 (2006.01) / Штриголь С. Ю., Подольський І. М., Зубков В. О., Гриценко І. С. – № а 2011 13575; заявл.: 18.11.2011; опубл.: 27.08.2013. – Бюл. № 16. – 4 с.

12. Podolsky, I. The analgesic properties of a promising antidepressant – 2-methyl-3-(phenylaminomethyl)-1H-quinolin-4-one / I. Podolsky, S. Shtrygol' // The Pharma Innovation Journal. – 2017. – Vol. 6, Issue 8 (C). – P. 156–160.

13. Council Directive 2010/63/EU of 22 September 2010 on the protection of animals used for scientific purposes // Official Journal of the European Communities. – 2010. – L 276. – P. 33–79.

14. 3-Диметиламинометил-2-метил-1Н-хинолин-4-он – эффективный реагент в синтезе 3-аминометилзамещенных хинолонов / В. А. Зубков, И. С. Гриценко, С. Г. Таран [та ін.] // Журнал органічної та фармацевтичної хімії. – 2005. – Т. 3, № 2 (10). – С. 23–27.

15. The tail suspension test: a new method for screening antidepressants in mice / L. Steru, R. Chermat, B. Thierry, P. Simon // Psychopharmacology (Berl). – 1985. – Vol. 85. – P. 367–370. https://doi.org/10.1007/bf00428203

16. The Influence of Red Light Exposure at Night on Circadian Metabolism and Physiology in Sprague-Dawley Rats // R. T. Dauchy, M. A. Wren, E. M. Dauchy [et al.] // J. Am. Assoc. Lab. Anim. Sci. – 2015. – Vol. 54, Issue 1. – P. 40–50.

17. Штрыголь, С. Ю. Модуляция фармакологических эффектов при различных солевых режимах: Монография / С. Ю. Штрыголь. – Харьков : Ависта-ВЛТ, 2007. – 360 c.

18. Cornelissen, G. Cosinor-based rhythmometry / G. Cornelissen // Theor. Biol. Med. Model. – 2014. – Vol. 11, Issue 1. – P. 1–24. https://doi.org/10.1186/1742-4682-11-16

19. Analgesic, Anxiolytic and Anaesthetic Effects of Melatonin: New Potential Uses in Pediatrics / L. Marseglia, G. D’Angelo, S. Manti [et al.] // Int. J. Mol. Sci. – 2015. – Vol. 16, Issue 1. – P. 1209–1220. https://doi.org/10.3390/ijms16011209




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)